NCI-sponsored Cancer Clinical Trials Have Become More Diverse Over Past Two Decades
ORLANDO, Fla. – Compared to the year 2000, a greater proportion of NCI-sponsored early-phase clinical trial participants in 2022...
ORLANDO, Fla. – Compared to the year 2000, a greater proportion of NCI-sponsored early-phase clinical trial participants in 2022...
Patients were matched to therapies targeting specific mutations found in their cancers PHILADELPHIA – Genomic sequencing of tumors from...
SAN ANTONIO – Jeffrey M. Rosen, PhD, will receive the William L. McGuire Memorial Lecture Award at the 2022...
ORLANDO, Fla. – Structural racism was associated with increased county-level cancer mortality rates among minority populations compared with whites,...
ORLANDO, Fla. – A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical...
PHILADELPHIA – The American Association for Cancer Research (AACR) has announced Graham A. Colditz, MD, DrPH, MPH, as the...
Palliative care use increased among all racial/ethnic groups from 2004 to 2020 ORLANDO, Fla. – Despite a steady increase...
PHILADELPHIA – The Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research will...
Modifying criteria could help researchers enroll more Black patients in trials PHILADELPHIA – A simulated pancreatic cancer clinical trial...
Latinos are also more likely to be diagnosed with this cancer type NEW ORLEANS – Some Latino children diagnosed...
PHILADELPHIA – The American Association for Cancer Research (AACR) today announced the appointment of Christine A. Iacobuzio-Donahue, MD, PhD,...
PHILADELPHIA – The American Association for Cancer Research (AACR) today announced the appointment of Massimo Loda, MD, as the...
SAN ANTONIO – Black women experienced higher rates of breast cancer-related lymphedema than white women, and Black race was...
Second- and third-generation individuals living in Los Angeles had a 35 and 61 percent higher risk, respectively, than those...
Transgender or gender non-conforming cancer survivors had higher odds of most conditions compared to cisgender cancer survivors PHILADELPHIA –...
PHILADELPHIA – Most LGBTQI+ patients with cancer report that they did not have access to health education materials tailored...
PHILADELPHIA – Intravenous immunoglobulin (IVIg) reduced the risk of severe infections by 90% in patients with multiple myeloma undergoing...
Less than half of the eligible families in the study were receiving federal food assistance benefits, and the majority...
PHILADELPHIA – Black women treated with neoadjuvant endocrine therapy for breast cancer were more likely to benefit than white...
SAN ANTONIO – Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in...
SAN ANTONIO – Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine...
LOS ANGELES – The American Association for Cancer Research (AACR) will award Scarlett Lin Gomez, MPH, PhD, with the...
PHILADELPHIA – The American Association for Cancer Research (AACR) has announced Loïc Le Marchand, MD, PhD, MPH, as the...
Patients with recurrent lesions genetically distinct from the primary tumor may require different treatment NEW ORLEANS – More than...
ORLANDO, Fla. – The American Association for Cancer Research (AACR) will award Folakemi T. Odedina, PhD, with the 2023...
NEW ORLEANS – Natural killer (NK) cells derived from cord blood that were activated and complexed with a CD30/CD16A...
The HPV vaccine has made near-elimination of cervical cancer possible, but health care disparities may delay this milestone PHILADELPHIA...
PHILADELPHIA – Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival...
SAN DIEGO – Patients with cancer who were living with human immunodeficiency virus (HIV) infection had increased epigenetic age—a...
Two-year follow up of the CodeBreaK 100 clinical trial demonstrated prolonged tumor responses and a favorable safety profile NEW...